加巴喷丁市场－全球产业规模、份额、趋势、机会和预测，按剂型、类型、应用、配销通路、地区和竞争格局划分，2020-2030年预测

2024年全球加巴喷丁市场规模为20.4亿美元，预计2030年将以5.60%的复合年增长率成长至28.3亿美元。加巴喷丁是一种抗惊厥药物，主要用于治疗神经性疼痛，并作为癫痫局部性发作的辅助治疗药物。慢性神经系统疾病（如癫痫和各种形式的神经性疼痛）盛行率的不断上升，以及老年人口的成长（老年人更容易患上这些疾病），是推动全球加巴喷丁市场成长的主要因素。

主要市场驱动因素

神经性疼痛疾病的日益普遍显着推动了全球加巴喷丁市场的发展，因为该药物是治疗此类疾病的主要选择之一。神经性疼痛是由神经损伤或疾病引起的，通常表现为慢性且令人痛苦的疼痛，因此需要有效的药物介入。

主要市场挑战

针对加巴喷丁潜在的误用、滥用和超适应症用药风险，监管机构日益严格的审查给全球市场带来了重大挑战。这种监管力度的加强促使多个司法管辖区实施更严格的监测方案，或将加巴喷丁重新归类为管製药物，这直接影响了其可近性和处方率。

主要市场趋势

缓释製剂的进步是影响全球加巴喷丁市场的重要因素，这主要得益于製药业致力于提高病患依从性和治疗效果。这些创新製剂的优点在于减少了给药频率，这对于治疗神经性疼痛等慢性疾病的患者至关重要，有助于提高患者的用药依从性，并更稳定地控制症状。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球加巴喷丁市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按剂型（锭剂、胶囊、口服溶液）
  • 按类型（通用名、品牌名）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 依适应症（癫痫、神经性疼痛、不宁腿症候群、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美加巴喷丁市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲加巴喷丁市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区加巴喷丁市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲加巴喷丁市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美加巴喷丁市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球加巴喷丁市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Zydus Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Sun Pharmaceutical Industries Ltd.
• Ascend Laboratories, LLC
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma.
• Amneal Pharmaceuticals LLC.
• Cipla Ltd.
• BP Pharmaceuticals Laboratories Company

第十六章：策略建议

第17章调查会社について・免责事项

The Global Gabapentin Market, valued at USD 2.04 Billion in 2024, is projected to experience a CAGR of 5.60% to reach USD 2.83 Billion by 2030. Gabapentin, an anticonvulsant medication, is primarily utilized for managing neuropathic pain and as an adjunct therapy for partial seizures in epilepsy. The global market for gabapentin is significantly driven by the increasing prevalence of chronic neurological conditions, such as epilepsy and various forms of neuropathic pain, alongside the expanding geriatric population, which is more susceptible to these disorders.

Key Market Drivers

The rising prevalence of neuropathic pain disorders significantly drives the global gabapentin market, as the medication is a primary treatment option for these conditions. Neuropathic pain, resulting from nerve damage or disease, often presents as chronic and debilitating, necessitating effective pharmaceutical interventions. According to a February 2024 article published in PubMed Central titled 'Shedding light on neuropathic pain: Current and emerging tools for diagnosis, screening, and quantification', the estimated prevalence of neuropathic pain in Europe is 7%-8%.

Key Market Challenges

Increasing regulatory scrutiny regarding gabapentin's potential for misuse, abuse, and off-label prescribing presents a significant challenge to the global market. This heightened oversight has prompted various jurisdictions to implement stricter monitoring protocols or reclassify gabapentin as a controlled substance, which directly affects its accessibility and prescription rates. Such reclassification introduces administrative complexities for healthcare providers and pharmacists, increasing the burden associated with prescribing and dispensing.

Key Market Trends

Advancements in Extended-Release Formulations are a significant factor shaping the global gabapentin market, driven by the pharmaceutical industry's focus on enhancing patient compliance and therapeutic outcomes. These innovative formulations offer advantages by reducing the frequency of dosing, which is crucial for individuals managing chronic conditions such as neuropathic pain, thereby promoting consistent medication adherence and more stable symptom control.

Key Market Players

• Zydus Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Sun Pharmaceutical Industries Ltd.
• Ascend Laboratories, LLC
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma.
• Amneal Pharmaceuticals LLC.
• Cipla Ltd.
• BP Pharmaceuticals Laboratories Company

Report Scope:

In this report, the Global Gabapentin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gabapentin Market, By Form:

• Tablet
• Capsule
• Oral Solution

Gabapentin Market, By Type:

• Generic
• Branded

Gabapentin Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Gabapentin Market, By Application:

• Epilepsy
• Neuropathic Pain
• Restless Legs Syndrome
• Others

Gabapentin Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gabapentin Market.

Available Customizations:

Global Gabapentin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gabapentin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Form (Tablet, Capsule, Oral Solution)
  • 5.2.2. By Type (Generic, Branded)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.4. By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Gabapentin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Form
  • 6.2.2. By Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Application
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gabapentin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Form
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Distribution Channel
      • 6.3.1.2.4. By Application
  • 6.3.2. Canada Gabapentin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Form
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Distribution Channel
      • 6.3.2.2.4. By Application
  • 6.3.3. Mexico Gabapentin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Form
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Distribution Channel
      • 6.3.3.2.4. By Application

7. Europe Gabapentin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Form
  • 7.2.2. By Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Application
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gabapentin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Form
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Distribution Channel
      • 7.3.1.2.4. By Application
  • 7.3.2. France Gabapentin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Form
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Distribution Channel
      • 7.3.2.2.4. By Application
  • 7.3.3. United Kingdom Gabapentin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Form
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Distribution Channel
      • 7.3.3.2.4. By Application
  • 7.3.4. Italy Gabapentin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Form
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Distribution Channel
      • 7.3.4.2.4. By Application
  • 7.3.5. Spain Gabapentin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Form
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Distribution Channel
      • 7.3.5.2.4. By Application

8. Asia Pacific Gabapentin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Form
  • 8.2.2. By Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Application
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gabapentin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Form
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Distribution Channel
      • 8.3.1.2.4. By Application
  • 8.3.2. India Gabapentin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Form
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Distribution Channel
      • 8.3.2.2.4. By Application
  • 8.3.3. Japan Gabapentin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Form
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Distribution Channel
      • 8.3.3.2.4. By Application
  • 8.3.4. South Korea Gabapentin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Form
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Distribution Channel
      • 8.3.4.2.4. By Application
  • 8.3.5. Australia Gabapentin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Form
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Distribution Channel
      • 8.3.5.2.4. By Application

9. Middle East & Africa Gabapentin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Form
  • 9.2.2. By Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Application
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gabapentin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Form
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Distribution Channel
      • 9.3.1.2.4. By Application
  • 9.3.2. UAE Gabapentin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Form
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Distribution Channel
      • 9.3.2.2.4. By Application
  • 9.3.3. South Africa Gabapentin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Form
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Distribution Channel
      • 9.3.3.2.4. By Application

10. South America Gabapentin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Form
  • 10.2.2. By Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Application
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gabapentin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Form
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Distribution Channel
      • 10.3.1.2.4. By Application
  • 10.3.2. Colombia Gabapentin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Form
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Distribution Channel
      • 10.3.2.2.4. By Application
  • 10.3.3. Argentina Gabapentin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Form
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Distribution Channel
      • 10.3.3.2.4. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gabapentin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zydus Pharmaceuticals, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Glenmark Pharmaceuticals Limited
• 15.3. Sun Pharmaceutical Industries Ltd.
• 15.4. Ascend Laboratories, LLC
• 15.5. Apotex Inc.
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Aurobindo Pharma.
• 15.8. Amneal Pharmaceuticals LLC.
• 15.9. Cipla Ltd.
• 15.10. BP Pharmaceuticals Laboratories Company

16. Strategic Recommendations

17. About Us & Disclaimer